CD5L and chronic myelogenous leukemia, BCR-ABL1 positive: More importantly, mean plasma concentration of CD5L in the pre-treated CP-CML subjects was 16.60 ± 7.99 ng/ml, which is nearly seven-times higher than the control group (2.29 ± 1.23 ng/ml).